COMMUNIQUÉS West-GlobeNewswire

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
23/10/2025
Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancer 64% overall [...]
Tango Therapeutics Announces $225 Million Financing
23/10/2025
Financing participants include Farallon Capital Management, TCGX, Balyasny Asset Management, Woodline Partners LP, Nextech, Invus, Adage Capital Management LP, Boxer Capital Management, Logos Capital, Nantahala Capital [...]
Cronos Group Inc. to Hold 2025 Third Quarter Earnings Conference Call on November 6, 2025
23/10/2025
TORONTO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2025 third quarter earnings conference call on Thursday, November 6, 2025 at 8:30 a.m. ET [...]
Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results
23/10/2025
MALVERN, Pa., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a [...]
Bionano Highlights Global Momentum Behind OGM at the 2025 Annual Meeting of the American Society of Human Genetics (ASHG) Meeting
23/10/2025
SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) participated in The American Society of Human Genetics (ASHG) conference from October 14–18, 2025 in Boston. The event highlighted the [...]
Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer
23/10/2025
Atlantic Health, a leading provider of health care based in New Jersey, to conduct the investigator-initiated Phase 1B/2 study Preclinical studies indicate Annamycin targets key factors in pancreatic cancer HOUSTON, Oct [...]
Oncotelic to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus)
23/10/2025
Accepted Presentations Showcase First-in-Human Development, Manufacturing Innovation, and Predictive Biomarkers for Deciparticle™ Everolimus (Sapu003) AGOURA HILLS, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Oncotelic [...]
Beyond Air Schedules Second Fiscal Quarter 2026 Financial Results Conference Call and Webcast
23/10/2025
GARDEN CITY, N.Y., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of [...]
Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review
23/10/2025
PRINCETON, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable [...]
LifeMD to Report Third Quarter 2025 Financial Results on November 6
23/10/2025
NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD) , a leading provider of virtual primary care services, announces that it will report financial results for the three and nine months ended [...]
Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025
23/10/2025
STOUGHTON, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report third quarter 2025 financial results before the market opens on Thursday, November 6 [...]
Glucose Health, Inc. Appoints Veteran Financial Executive Edmund “Ned” Burke to Its Board of Directors
23/10/2025
BENTONVILLE, Ark., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC) is pleased to announce the appointment of Edmund (Ned) Burke, a highly accomplished financial services executive, to its Board of [...]
Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting
23/10/2025
Preliminary analysis of one-year progression-free survival data from Phase 2 study of novel SST2 agonist paltusotine under investigation for carcinoid syndrome demonstrated potential anti-tumor effects SAN DIEGO, Oct. [...]
Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10ᵗʰ ESWI Influenza Conference 2025
23/10/2025
SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced [...]
Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025
23/10/2025
CLEARWATER, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and [...]
Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®
23/10/2025
-- Findings Presented at AMCP Nexus 2025 Annual Meeting -- BRISBANE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain [...]
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting
23/10/2025
FLORHAM PARK, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) [...]
BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society
23/10/2025
SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the [...]
SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)
23/10/2025
Company launches multi-channel promotional campaign to drive market adoption U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli ™ as the first FDA-approved [...]

Pages